Table 3.
Within-group change in biochemical indices of bone mineral metabolism
| Antiepileptic drug group
|
||||||||
|---|---|---|---|---|---|---|---|---|
| CBZ
|
LTG
|
PHT
|
VPA
|
|||||
| Baseline | 1 Year | Baseline | 1 Year | Baseline | 1 Year | Baseline | 1 Year | |
| Serum Ca | 9.5 ± 0.5 | 9.6 ± 0.5 | 10.0 ± 0.4 | 10.0 ± 0.0.4 | 9.6 ± 0.4 | 9.6 ± 0.3 | 9.4 ± 0.9 | 9.6 ± 0.4 |
|
| ||||||||
| 25-OHD | 25.3 ± 6.8 | 23.4 ± 7.2 | 23.8 ± 6.5 | 25.2 ± 7.0 | 23.3 ± 11.5 | 23.8 ± 10.7 | 25.9 ± 13.1 | 27.7 ± 15.7 |
|
| ||||||||
| 1,25(OH)2D | 37.8 ± 14.1 | 36.0 ± 11.6 | 35.9 ± 14.9 | 41.4 ± 13.5 | 33.4 ± 12.2 | 32.5 ± 9.6 | 32.2 ± 14.6 | 36.3 ± 19.4 |
|
| ||||||||
| PTH | 25.4 ± 9.6 | 29.8 ± 18.5 | 28.2 ± 14.9 | 24.4 ± 13.2 | 26.3 ± 13.0 | 32.0 ± 17.2 | 22.7 ± 12.4 | 22.0 ± 12.3 |
|
| ||||||||
| BSAP | 23.0 ± 6.5 | 23.1 ± 7.3 | 19.6 ± 6.5 | 20.8 ± 6.8 | 22.6 ± 5.9 | 26.0 ± 5.7 | 18.6 ± 6.2 | 18.8 ± 7.9 |
|
| ||||||||
| Osteocalcin | 8.2 ± 3.3 | 9.0 ± 3.9 | 9.2 ± 3.3 | 9.4 ± 3.3 | 8.3 ± 4.9 | 8.7 ± 4.2 | 10.1 ± 4.6 | 9.0 ± 3.2 |
|
| ||||||||
| Serum NTx | 12.2 ± 2.2 | 12.5 ± 3.3 | 12.4 ± 2.8 | 13.8 ± 4.2 | 12.9 ± 2.3 | 14.0 ± 1.8 | 12.5 ± 3.0 | 13.2 ± 2.0 |
|
| ||||||||
| Urine NTx | 42.4 ± 24.5 | 43.4 ± 27.9 | 35.0 ± 18.2 | 35.3 ± 17.8 | 55.9 ± 44.1 | 45.4 ± 25.1* | 50.4 ± 31.2 | 43.8 ± 24.4 |
Data are expressed as mean ± SD.
*
Within-drug group change from baseline p value < 0.05.
CBZ = carbamazepine; LTG = lamotrigine; PHT = phenytoin; VPA = valproate; 25-OHD = 25-hydroxyvitamin D; 1,25(OH)2D = 1,25-dihydroxyvitamin D; PTH = parathyroid hormone; BSAP = bone-specific alkaline phosphatase; NTx = cross-linked N-telopeptide of type I bone collagen.